Mallinckrodt

Dublin, Irelandmallinckrodt.com1expert edge

Specialty pharmaceutical company with portfolio spanning branded and generic drugs; announced $6.7B merger with Endo in March 2025 to create scaled diversified pharma company.

Why interesting to a deal team

Expert advised on major $6.7B pharma merger combining complementary portfolios; demonstrates large-cap M&A and restructuring expertise.

Experts connected to this company

Eric StewartAdvised on $6.7bn merger with Endo

Eric Stewart

Senior Managing Director, European M&A

Leerink Partners

Fund GPLondon

Stewart built Leerink's European healthcare M&A practice from scratch, bringing a decade of Lazard deal relationships spanning Mallinckrodt, Abcam/Danaher and Galderma.

Sources

Page titleOther
investor.endo.com/2025-03-13-Mallinckrodt-and-Endo-to-Combine-to-Create-a-Global,-Scaled,-Diversified-Pharmaceuticals-Leader
Page titleOther
biospace.com/business/troubled-drugmakers-mallinckrodt-endo-officially-announce-6-7b-merger
Name + firmPrimary
mallinckrodt.com

Strongest evidencePage title3 public sourcesHow the grades work